As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/15/20  Mednax, Inc.                      8-K:5       1/13/20   10:134K                                   Donnelley … Solutions/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     24K 
 9: R1          Document and Entity Information                     HTML     47K 
 7: XML         IDEA XML File -- Filing Summary                      XML     11K 
10: XML         XBRL Instance -- d867690d8k_htm                      XML     13K 
 6: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.LAB  XBRL Labels -- md-20200113_lab                       XML     53K 
 4: EX-101.PRE  XBRL Presentations -- md-20200113_pre                XML     33K 
 2: EX-101.SCH  XBRL Schema -- md-20200113                           XSD     12K 
 5: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    18K 
 8: ZIP         XBRL Zipped Folder -- 0001193125-20-008166-xbrl      Zip      8K 

 i false  i 0000893949 0000893949 2020-01-13 2020-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM  i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):  i January 13, 2020

 i MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

i Florida		i 001-12111		i 26-3667538
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 i 1301 Concord Terrace

 i Sunrise,  i Florida  i 33323 

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code  i (954)  i 384-0175

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, par value $.01 per share		i MD		i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

MEDNAX, Inc., a Florida corporation (the “Company”), has eliminated the role of chief operating officer of the Company, effective as of December 31, 2019, as part of the Company’s previously announced transformation and restructuring plan. In connection with this change, the Company’s chief operating officer, Mr. David A. Clark, departed the Company on January 13, 2020, also effective as of December 31, 2019. Mr. Clark’s departure from the Company is a termination without “Cause,” as defined in that certain employment agreement, dated February 12, 2019, by and between a wholly-owned subsidiary of the Company and Mr. Clark.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				MEDNAX, INC.
Date: January 15, 2020				By:		/s/ Stephen D. Farber
						Stephen D. Farber Chief Financial Officer